|FRONTBIO Inc. Presented at Pharmaceutical Science 2021 "anti cancer mechanism"|
|작성일 : 2021-10-15 조회수 : 53|
FRONTBIO Inc. Presented at Pharmaceutical Science 2021 Disclosure of ‘Cancer cell-specific active oxygen amplification mechanism complex anticancer drug’ Mechanism, etc.
FRONTBIO, a new drug development bio company, announced on October 15th that CEO Lee Jae-Yong had been invited as a speaker to the 5th International Pharmaceutical and Advanced Drug Delivery System 2021 of AAC for the Study of Pharmaceuticals and Health Care, which was held on the Cisco WebEx conference platform.
Pharmaceutical Science 2021 is an authoritative international academic conference that brings together new drug development experts from over 100 countries to discuss
information on new drug development trends and technologies.
At this conference, FRONTBIO verbally announced the development of a complex anticancer drug with a new mechanism that can selectively amplify and kill oxygen
free radicals only in cancer cells by using the difference in energy metabolism between normal cells and cancer cells.
CEO Jae-Yong Lee said, “The mode of action of the complex anticancer drug currently being developed binds to the electron transport complex in the mitochondria activate
AMPK, FOXO3a, and MnSOD. Mechanism of 'Cancer Cell-Specific ROS Amplifier (CASRA)' that protects n amplifies oxygen free
radicals in cancer cells to induce apoptosis, autophagy, and necroptosis cell death through gene damage of anticancer drugs,”
FRONTBIO has completed preclinical testing of anticancer drugs and is currently conducting finished drug safety testing. It plans to submit an IND for a phase 1
clinical trial this year and begin the trial in the first half of 2022.
FRONTBIO CEO Lee Jae-Yong says, "We will do our best to achieve results such as signing a partnership with clinical and global pharmaceutical companies and transferring technology through continuous attendance at academic conferences and presentation of papers."
In the meantime, the findings of this study were published in July in 'Scientific Reports,' a sister journal to the international academic journal Nature.
|다음글||FRONTBIO Inc. Published a Paper to Identify New Anticancer Mechanism ‘CASRA’|
- Press Releases